Prof. Lüscher paints a picture of how atherosclerosis has been a fact of human life throughout time, and the evolution of insights on how to lower LDL-c and its associated CV risk.

Presence of calcified plaques have been found in the mummified remains of three of four studied young Inuit individuals who lived 500 years ago.

AHA 2019 The 9-months data of the EVAPORATE study show slowing of several markers of plaque progression, although the primary endpoint of low attenuation plaque was not met.

Exploratory analysis identifies predictors of plaque erosion in patients with ACS who underwent OCT imaging. A combination of non-traditional risk factors can increase the probability of erosion to up to 73%.

Final results from the open-label OSLER-1 study on evolocumab show long-term reduction in LDL-C levels without attenuation of the LDL-lowering effect and consistent safety and tolerability profiles during 5-years.

Prof. Jukema explains the mechanism of epigenetics and how the BET inhibitor apabetalone can potentially impact CVD. In addition, he presents findings of first clinical studies with apabetalone.

Phase 3 ORION-11 results up to 18 months show efficacy of inclisiran, which prevents production of the PCSK9 protein, consistent with earlier studies and an at least as favorable safety profile.

In subjects without established CVD, assessment of CAC contributes to identify high-risk subjects who will benefit from low dose rivaroxaban.

A CAC score>100 was associated with increased risk of CHD, CVD and all-cause mortality compared to CAC score of 0 in adults between 30-49 years.

EAS 2019 Professor Helen Hobbs is the recipient of this year’s Anitschow Award. She shared her work on how a SNP in PNPLA3 leads to hepatic steatosis, and potential therapeutic strategies to prevent the disease.

The PALM registry reveals that 27% of adults who were eligible for statin therapy, did not use it. In almost 60%, this was because they were never offered a statin. Others discontinued, or declined use

Use of apixaban resulted in slower progression of coronary atherosclerotic and calcified plaques compared to warfarin in AF patients, measured by CTA.